GLPG-3970 clinical trials
Also written GLPG3970.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses GLPG-3970 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLPG-3970 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy SubjectsCompletedPhase 1Galapagos NVNCT04720183Written as GLPG3970
- A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970CompletedPhase 1Lakefront Biotherapeutics NVNCT04106297Written as GLPG3970 oral solution
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)TerminatedPhase 2Galapagos NVNCT04700280Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisCompletedPhase 2Galapagos NVNCT04577794Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedPhase 2Galapagos NVNCT04577781Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus ErythematosusTerminatedPhase 1Galapagos NVNCT04700267Written as GLPG3970 film-coated tablet
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970CompletedPhase 1Galapagos NVNCT04907149Written as GLPG3970 film-coated tablet
- A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970CompletedPhase 1Galapagos NVNCT04708184Written as GLPG3970 oral solution